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Purpose: To investigate if specific exon 38 or 39 KMT2D missense
variants (MVs) cause a condition distinct from Kabuki syndrome
type 1 (KS1).
Methods: Multiple individuals, with MVs in exons 38 or 39 of
KMT2D that encode a highly conserved region of 54 amino acids
flanked by Val3527 and Lys3583, were identified and phenotyped.
Functional tests were performed to study their pathogenicity and
understand the disease mechanism.
Results: The consistent clinical features of the affected individuals,
from seven unrelated families, included choanal atresia, athelia or
hypoplastic nipples, branchial sinus abnormalities, neck pits,
lacrimal duct anomalies, hearing loss, external ear malformations,
and thyroid abnormalities. None of the individuals had intellectual
disability. The frequency of clinical features, objective software-
based facial analysis metrics, and genome-wide peripheral blood
DNA methylation patterns in these patients were significantly
different from that of KS1. Circular dichroism spectroscopy
indicated that these MVs perturb KMT2D secondary structure
through an increased disordered to ɑ-helical transition.
Conclusion: KMT2D MVs located in a specific region spanning
exons 38 and 39 and affecting highly conserved residues cause a
novel multiple malformations syndrome distinct from KS1. Unlike
KMT2D haploinsufficiency in KS1, these MVs likely result in
disease through a dominant negative mechanism.
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0743-3
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INTRODUCTION
Diverse developmental phenotypes resulting from distinct
variants in the same gene are being increasingly recognized,
largely due to wider application of next-generation sequen-
cing and multicenter collaborations.1 These discoveries
provide unique biological insights into gene and protein
functions, and are critical for appropriate medical manage-
ment, and counseling of patients and families.
Defective histone lysine methylation and chromatin remo-
deling defects underlie several congenital malformation
disorders.2 KMT2D encodes a very large (593 kDa) protein
that catalyzes the mono-, di-, and trimethylation of the lysine
4 on histone 3 (H3K4) in a multiprotein complex.3 The
KMT2D protein contains multiple known domains; however,
the structure and function of several regions of the KMT2D
protein remain unresolved. KMT2D also has a high level of
predicted disorder content (55%) with many regions of
intrinsic disorder, which are typical features of nuclear
proteins that regulate transcription and chromatin organiza-
tion.4 Kabuki syndrome type 1 (KS1, MIM 147920) is an
autosomal dominant condition caused by loss-of-function
KMT2D (MIM 602113) variants.5 Over 700 KMT2D variants
have been reported in the literature in individuals with KS1.
Approximately 80% of germline KMT2D variants causative
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for KS1 are predicted to be protein truncating and are thought
to result in functional haploinsufficiency due to nonsense-
mediated decay.6 In rare instances, individuals with KS1 have
also been described to have a whole-gene deletion.7 Germline
KMT2D missense variants (MVs) causative for KS1 cluster in
certain functional regions of the protein, such as in the PHD
fingers, RING-type zinc fingers, the FYR-N domain and the
SET domain6 (Fig. 1a–c). Notably, germline MVs in some
highly conserved regions of the protein have not yet been
described in individuals with KS1.6 KS1 is characterized by
neonatal hypotonia, feeding difficulties during infancy and
early childhood, postnatal growth deficiency, skeletal anoma-
lies, immune dysfunction, endocrine abnormalities, and
congenital malformations of the heart, kidney, and palate.8
Almost all individuals with KS1 show global developmental
delay and intellectual disability. Facial dysmorphism is the
most distinguishing feature of the condition and is typically
characterized by interrupted eyebrows, long palpebral fissures,
eversion of the lateral part of the lower eyelids, large cupped
ears, short columella, bulbous nasal tip, and pillowed lower
lip.8,9 Here, we describe clustering of heterozygous KMT2D
MVs, in a highly conserved central region of the protein, as
causative of a novel phenotype with multiple malformations
that is clinically and epigenetically distinct from KS1.
MATERIALS AND METHODS
Patient ascertainment, clinical characterization, and genetic
studies
Ethical approval for molecular genetics research studies was
obtained from the Research Ethics Committees of South
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Fig. 1 Affected individuals have missense variants in parts of exons 38 or 39 of KMT2D. We studied multiple affected individuals from seven
families with missense KMT2D variants restricted to a region that encodes for 54 amino acids flanked by Val3527 and Lys3583 (ENST00000301067.7;
NM_003482.3). (a) Schematic representation of KMT2D exons with each alternating exon represented in dark or light red shade (introns are not depicted).
(b) Frequency of KMT2D missense variants (from gnomAD) in the general population is shown in yellow. Deeper troughs represent higher frequency at that
particular location. (c) Green lollipop graph denoting the missense KMT2D variants in individuals with Kabuki syndrome from the published literature.6 The
y-axis in this graph represents the frequency of the variant in the published literature. The x-axis is a schematic for the protein denoting the location of
important domains and regions of KMT2D. Note that variants identified in this study are located in parts of exons 38 and 39 with high missense constraint
but without any variants in individuals with Kabuki syndrome. (d) The region of interest of the KMT2D gene and protein in more detail. The red horizontal
bar shows parts of exons 38 (amino acid 3503–3580) and 39 (amino acid 3581–4510). The blue vertical bars denote the coiled-coil regions. Red lines
indicate the location of the variants identified in this study. Pedigree of each family is shown under the corresponding variant. Standard symbols are used to
denote affected (filled symbols) and unaffected (unfilled) individuals. All individuals who were tested but not found to carry familial KMT2D variants are
denoted by “N”. Father in family 4 (F4; I:1) was found to be likely mosaic and is denoted by gray square. In this family, genetic testing was not possible for
the first born child (F4; II:1) but is shown as affected based on the clinical history.
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Yorkshire (11/H1310/1), North West—Greater Manchester
South (11/H1003/3), Cambridge South (10/H0305/83), the
Republic of Ireland (GEN/284/12), Al-Ain Medical Human
Research (ERH2015-3241-15-115), and East of England—
Cambridge South (14/EE/1112). Informed consent for
research studies was obtained from all participating families
or individuals, as was permission to publish patient
photographs. Ascertainment was driven by genotype in
the first six families in whom KMT2D MVs of uncertain
significance were identified by multigene panel testing or
genome sequencing (GS) or exome sequencing (ES). The
affected individual in family 7 was identified via targeted
testing due to phenotypic similarity with other individuals
described in this paper. All affected individuals underwent
detailed clinical phenotyping (Table S1). Confirmation and
segregation of all KMT2D variants was performed using
conventional Sanger sequencing.
Total RNAs were extracted using RNeasy Mini kit (Qiagen)
according to the manufacturer’s protocol and quantitative
reverse transcription polymerase chain reaction (RT-qPCR)
was performed using standard methods.
Facial analysis
Ten previously unpublished photographs at different ages of
six individuals in Ex38/39 KMT2D MVs cohort were
uploaded onto and the results were obtained using the
Face2Gene RESEARCH application (FDNA Inc., Boston,
MA) for objective analysis of facial dysmorphology. Compar-
ison was made with two groups of photographs of ten
individuals, each with molecularly confirmed KS1 or
CHARGE syndrome (OMIM 214800). The sensitivity and
specificity of this classification system was analyzed by
receiver operating characteristic (ROC) curves, and the
corresponding area under the curve (AUC) and p values
were calculated as described previously.10
Peripheral blood DNA methylation
Peripheral blood was collected in EDTA tubes and genomic
DNA was isolated using QIAamp DNA blood mini kit
(Qiagen). Unmethylated cytosines were converted to uracil
through bisulfite conversion using Zymo EZ DNA Methy-
lation kit (Zymo Research). Genome-wide methylation was
studied using Infinium MethylationEPIC BeadChip Kit
(Illumina) (hereafter referred to as EPIC array) according
to the manufacturer’s protocol. The array was stained and
scanned using the Illumina iScan System. Data were
processed using standard methods (Supplementary meth-
ods). Due to small number of samples and differences in
ages of our patients and controls, we removed known age-
associated probes.11–13 Principal component analysis
(PCA) was used to visualize clustering of the samples
based on differentially methylated positions (DMPs)
between groups (p < 0.001). Overlap of DMPs between
groups was assessed using InteractiVenn web based tool.14
Gene ontologies associated with DMPs were assessed using
canonical pathway analysis (Ingenuity pathway analysis
software, Qiagen, San Francisco, CA). Differentially
methylated regions of the chromosome (DMRs) (>7
annotated CpGs) were analyzed on EPIC array data using
the Bumphunter method15 in the Bioconductor package
ChAMP.16
H3K4me3 methylation
The pFlag-CMV2 FUSION–KMT2D construct17 was mod-
ified by inserting sequences for KMT2D that encode residues
3387–3697. Expression plasmids harboring KMT2D missense
variants were generated by site-directed mutagenesis accord-
ing to standard methods. HEK-293T cells were cultured in
Dulbecco’s Modified Eagle Medium with 10% fetal bovine
serum, penicillin (100 U/ml) and streptomycin (100 mg/ml)
(Life Technologies). HEK-293T cells were transiently trans-
fected using the polyethylenimine method, following pub-
lished protocols.18 Cells were harvested 48 hours after
transfection and used for protein extraction and histone
methyltransferase assay. HEK-293T cells were plated in 12-
well culture dishes at a density of 2.5 × 104 cells/ml and then
FLAG-KMT2D wild-type or mutated constructs were
cotransfected together with an epigenetic reporter allele
(“methyl reader”).19 Forty-eight hours after transfection, cells
were washed and resuspended in 100 μl phosphate buffered
saline (PBS) and subsequently plated into 96-well plates with
black flat bottom (Corning®). The fluorescence signal was
monitored using a Glomax 96 microplate luminometer (blue
filter, Ex= 475 nm; Em= 500–550 nm) and was normalized
to the methyl reader signal. Three or more biological
replicates were performed for all assays.
Protein analysis
Coiled-coil domains were predicted by MARCOIL, a
hidden Markov model–based program that predicts the
existence and location of potential coiled-coil domains in
protein sequences.20 MultiCoil was used for predicting
two- and three-stranded coiled coils.21 Gene synthesis of
the wild-type and mutant sequences for KMT2D that
encode residues 3231–3600 or 3503–3600 was carried out
by GENEWIZ Inc. (South Plainfield, NJ). The sequences
were subcloned into the bacterial expression vector
pOPINF22 with a polyhistidine (6xHis) tag. Standard
methods were followed for optimization of soluble
recombinant protein expression at 12 °C in E. coli
“ArcticExpress” cells (Agilent Technologies) and affinity
purification with nickel-charged affinity resin columns
(Ni-NTA Agarose) using fast protein liquid chromatogra-
phy (ÄKTA Chromatography System, GE Healthcare Life
Sciences). Protein purity was assessed by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
and western blotting. Purified proteins were buffer
exchanged into 100 mM phosphate buffer, pH 7.2 (68.4
mM Na2HPO4, 31.6 mM NaH2PO4) and analyzed by
circular dichroism (CD) spectroscopy, using a Chirascan
Plus (Applied Photophysics) spectropolarimeter. Analyses
of experimental protein CD spectra were by DichroWeb.23
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RESULTS
Genetic studies
We ascertained multiple individuals from seven families with
missense variants restricted to a highly conserved region
of 54 amino acids flanked by Val3527 and Lys3583
(ENST00000301067.7; NM_003482.3) (Figs. 1d and 2a, b;
Fig. S1) (Supplementary case reports) (hereafter referred to as
Ex38/39 KMT2DMVs). Identical de novo heterozygous exon 38
KMT2D c.10582C>G p.(Leu3528Val) variants was identified in
probands of families 1 and 2. A de novo heterozygous exon 38
KMT2D c.10625T>C p.(Leu3542Pro) variant was identified
in the proband of family 3. In family 4 (previously reported by
Al-Gazali et al.21) and family 5 an identical heterozygous exon
38 KMT2D c.1658G>T p.(Gly3553Val) variant was seen in all
affected individuals available for testing. In family 4, where
multiple children were affected, the variant was shown to be
mosaic in their father (Fig. S2) and in family 5 the variant had
arisen de novo in the proband. In family 6, a heterozygous exon
39 KMT2D c.10745G>A p.(Arg3582Gln) variant was detected
in the proband and his similarly affected mother. A de novo
heterozygous exon 39 KMT2D c.10744C>T p.(Arg3582Trp)
variant, affecting the same residue that was substituted in family
6, was detected in family 7. Additional rare de novo or biallelic
variants identified in our studies were all classed as likely benign
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(Table S2). All KMT2D MVs affected highly conserved residues
(Fig. S1) and were absent in gnomAD, [Karczewski KJ, Francioli
LC, Tiao G, et al. Variation across 141,456 human exomes and
genomes reveals the spectrum of loss-of-function Q7 intoler-
ance across human protein-coding genes. 2019] dbSNP,24 and
ClinVar.25 The c.10744C>T (COSM431206) and c.10745G>A
(COSM4604032) variants were found in COSMIC26 (Table S1).
Overall, these results were highly indicative that the variants
were pathogenic.
Phenotype and facial analyses
As none of the patients were clinically diagnosed with KS, we
compiled the clinical features of all affected individuals in
detail (Fig. 2a, b) (Table 1). The most consistent clinical
features of the affected individuals identified here included
choanal atresia, athelia or hypoplastic nipples, branchial sinus
abnormalities, neck pits, abnormalities of the lacrimal ducts,
hearing loss, external ear malformations, and thyroid
abnormalities or functional thyroid disease.
To examine if the phenotype of the affected individuals is
distinct from that of KS1, we compared the frequencies of
major phenotypes observed in Ex38/39 KMT2D MVs cohort
and in individuals with KS1 (Table 2). Only hearing loss and
external ear abnormalities were consistent major features of
both conditions. In contrast, cleft lip or palate, renal
structural abnormalities, and seizures are common in KS1
but were absent in the Ex38/39 KMT2D MVs cohort. Due to
the clinical overlap, we also compared the frequencies of
phenotypes observed in the Ex38/39 KMT2D MVs cohort
with individuals with CHARGE syndrome. This comparison
also showed several differences (Table 2). External ear
malformations, although seen in all three groups are of
different nature (small or absent external ears in the Ex38/
39 KMT2D MVs cohort, large prominent ears in KS1, and
simple dysplastic in CHARGE syndrome). Markedly,
intellectual disability that is almost universal in KS1 and
CHARGE syndromes was absent in the Ex38/39 KMT2D
MVs cohort. As facial dysmorphism is the most specific and
sensitive feature of KS1,8,9 we performed computer-based
objective analyses based on syndrome-specific classifiers of
facial features. This showed that the facial features of
individuals in the Ex38/39 KMT2D MVs cohort were
significantly different to those with KS1 (AUC= 0.918;
p= 0.018) and CHARGE syndrome (AUC= 0.902; p=
0.025) (Fig. 2c, d). Overall, these analyses were highly
suggestive that the phenotype of the individuals described in
this study is distinct from that of Kabuki and CHARGE
syndromes.
Peripheral blood DNA methylation
Since DNA methylation signatures can differentiate patho-
genic and nonpathogenic KMT2D variants,27 we examined if
the epigenetic profile of the condition we described herein is
distinct from that of KS1. We compared the DNA methyla-
tion patterns in peripheral blood collected from the following
individuals: four affected individuals from the Ex38/39
KMT2D MVs cohort, four individuals with KS1, four with
CHARGE syndrome, and four controls (Table S3). We
validated our results by comparing them with the hypo-
and hypermethylated CpG sites in individuals with KS1 listed
by Butcher et al. (Fig. S3).27 The PCA analysis of the DNA
methylation profiles of samples from the Ex38/39 KMT2D
MVs cohort clustered together and differed from those of
controls, KS1, and CHARGE syndrome (Fig. 2e). Intersection
analysis showed that the samples from the Ex38/39 KMT2D
MVs cohort and KS1 share only 915 differentially methylated
CpG sites (p < 0.001) (Fig. S4). These results were highly
suggestive that Ex38/39 KMT2D MVs result in a condition
that is epigenetically distinct from both Kabuki and CHARGE
syndromes.
RT-qPCR
To explore the disease mechanism we studied the effect of
these variants on the expression of KMT2D. Fibroblasts were
obtained from two affected individuals from our cohort
(proband from family 7 and family 3) (Table S3) and one
Fig. 2 Missense KMT2D variants described in this study result in phenotype distinct from type 1 Kabuki and CHARGE syndromes. (a)
Photographs of individuals described here with missense KMT2D variants. Note the wide range of facial features. P2, proband from family 2, is shown at two
different ages. Note facial asymmetry, hypertelorism, bilateral epicanthic folds, bulbous nasal tip, downturned corners of the mouth, microtia, and
hypoplastic nipples. P3, proband from family 3, has a box-shaped head, bilateral microphthalmia, severely hypoplastic left pinna, and ectopic left external
auditory canal. P5 and P7, probands from families 5 and 7 respectively, have prominent forehead, broad nasal root, flat midface, and thin upper lip. P7’s
eyebrows are laterally flared. One individual with Kabuki syndrome type 1 (KS1) is shown for comparison. Note arched eyebrows, long palpebral fissures,
eversion of the lateral part of the lower eyelids, large cupped ears, short columella, bulbous nasal tip, and pillowed lower lip. In individual with CHARGE
syndrome note hypertelorism, bulbous and large nasal tip, and a repaired cleft lip. (b) Computerized tomography (CT) (i and ii) and T2-weighted magnetic
resonance imaging (MRI) (iii) of P2 demonstrating absence of the posterior part of the semicircular canals (red arrows) and normal anatomy of the lateral and
anterior semicircular canals. Brain MRI of P3 (iv) to show well-formed right and left middle ear cavities, with the right cavity being smaller than the left.
Bilaterally the cochlea, semicircular canals, and inner auditory canals appear normal. T1-weighted MRI to demonstrate a small left optic globe with
ballooning of the optic disc bilaterally (red arrows) and optic disc colobomata (v). CT imaging of P5 (vi, vii) demonstrating the presence of cysts in the lower
jaw (red arrows). (c) Face2Gene analysis with confusion matrix showing that the system is able to predict correctly each group with a mean accuracy of
75.44%. (d) Receiver operating characteristic (ROC) graphs show the probability curve where the area under the curve (AUC) (0–1) represents the measure
of separability between two groups. Score distributions show the distribution of those probabilities. The higher the AUC, the better the model is at
distinguishing between two groups. (e) Principal component analysis (PCA) shows the four groups analyzed in the DNA methylation array clustering
separately (p < 0.001). Importantly, the samples from individuals described in this study cluster together and separate from those with type 1 Kabuki
syndrome. MV missense variant.
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control. Using RT-qPCR, we observed no significant differ-
ences in the level of KMT2D expression in fibroblasts of
affected individuals compared with the control (Fig. S5).
Histone H3K4 methylation assays
To experimentally test the functional impact of KMT2D
missense variants, we generated FLAG-tagged versions of six
KMT2D missense alleles: p.Leu3528Val, p.Leu3542Pro, p.
Gly3553Val, p.Gln3575His,28 p.Arg3582Trp, and p.Arg3582Gln.
Fluorescence data revealed no changes in trimethylation H3K4
levels between all the missense variants tested in this assay
compared with KMT2D normal control activity (Fig. S6).
Protein analysis
As the variants did not appear to impact on KMT2D
expression or direct H3K4 trimethylation activity, we
considered the possibility that variants affected
protein–protein interactions with KMT2D. The variants
identified in this study do not occur in a known functional
domain of the protein, but are instead in a central, highly
conserved region that also contains short polyQ tracts
(Fig. S1). All of the variants occur within or close to a
coiled-coil domain (residues 3562–3614; Fig. 3a) predicted by
MARCOIL.20 Furthermore, MultiCoil21 identified heptad
repeat sequences that mediate a possible coiled-coil dimer
between residues 3506 and 3610 (heptad net plot, Fig. 3b).
Analysis of the CD spectrum of the KMT2D wild-type protein
fragment (3503–3600 residues, molecular weight 11.8 kDa) by
DichroWeb23 revealed the following predicted proportions of
secondary structure: 0.14 α-helix, 0.26 β-strand, 0.27 turn, and
0.32 disordered. A larger KMT2D wild-type protein fragment
(3231–3600 residues, molecular weight 40.7 kDa) had the
following proportions: 0.22 α-helix, 0.18 β-strand, 0.19 turn,
and 0.41 disordered (Fig. S7). All recombinant KMT2D
proteins with missense variants had perturbed secondary
structure with decreased disorder and increased proportions
of predicted α-helical structure (Fig. 3c).
Differentially methylated region analysis
We used the data generated from our peripheral blood DNA
methylation experiments to explore the likely dysregulated
pathways. Within the 5162 differentially methylated CpG sites
in Ex38/39 KMT2D MVs cohort compared with control
samples, we observed significant enrichment for CpG sites
corresponding to genes related to morphology of the head,
embryonic development, cell proliferation, and development
of body axis (Fig. S4). Next, we investigated the potential
disease mechanism by analyzing DMRs in the Ex38/39
KMT2D MVs cohort compared with control samples. We
identified 83 such DMRs including several genes associated
with clinical features, such as hearing impairment or
hypothyroidism, that we observed in the Ex38/39 KMT2D
MVs cohort (Table S4) (Fig. S4).
DISCUSSION
Multiple lines of evidence suggest that the Ex38/39 KMT2D
MVs identified in this study are the cause of the phenotypes
of the affected individuals. These include (1) the de novo
occurrence of the variants in five families (Fig. 1), (2)
segregation of the variants with the phenotype in a
multiplex family (family 6), (3) presence of variant in
mosaic state in an unaffected parent of another multiplex
family (family 4), (4) absence of these variants from control
databases, (5) identical variants in families 1 and 2 (p.
Leu3528Val) and in families 4 and 5 (p.Glu3553Val), (6)
distinct variants affecting the same codon in families 6 and
7 (p.Arg3582Glu) and (p.Arg3582Trp), (7) clustering of the
variants within a span of just 54 amino acids in a protein of
size 5537 amino acids with very strong evolutionary
Table 2 Comparison of the phenotype between our cohort
and type 1 Kabuki and CHARGE syndromes.
Feature Ex38/39
KMT2D MVs
Type 1 Kabuki
syndrome
CHARGE
syndrome
Branchial sinus/
neck pits
7/9 (78%) Not reported or
extremely rare
Not reported
or
extremely rare
Hearing loss 8/9 (89%) Common Common
External ear
abnormalities
6/9 (67%)
(small,
hypoplastic, or
absent)
Common
(usually
prominent and
simple)
Common
(usually
simple or
dysplastic)
Structural
abnormality of eye
2/9 (22%) Rare Common
Abnormality of
lacrimal ducts
7/9 (78%) Rare Rare
Choanal atresia 7/9 (78%) Rare Common
Cleft lip/palate 0 Common Common
Athelia/
hypoplastic nipples
6/9 (67%) Not reported
(prominent
breasts are
common)
Rare
Congenital heart
disease
3/9 (33%) Common Common
Renal structural
abnormality
0 Common Common
Seizures 0 Common Common
Intellectual
disability
0 Common Common
Feeding difficulties 5/9 (44%) Common Common
Short stature 5/9 (56%) Common Common
Thyroid
abnormality/
hypothyroidism
6/9 (67%) Rare Rare
Abnormality of
immune system/
recurrent
infections
4/9 (44%) Common Common
This table compares the clinical features of our cohort of individuals with missense
KMT2D variants with type 1 Kabuki and CHARGE syndromes. We have con-
sidered common and rare features as those that occur in >25% and <25% of
affected individuals, respectively. For the Ex38/39 KMT2D MVs cohort we have
excluded the individual (F4; I:1) with mosaic variant to calculate the frequencies of
the clinical features.
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conservation of all affected residues (Fig. S1), (8) strong
similarity of the phenotype in families 1–6 that were
ascertained on the basis of genotype, and (9) identification
of the variant in family 7 through targeted single-gene
phenotype-led testing (Table 1 and S1) (Fig. 2).
The affected individuals we describe share some features
with KS1, including hearing loss, dental anomalies, feeding
difficulties, failure to thrive, and abnormalities of the immune
system. However, the most commonly observed malforma-
tions in individuals with KS1, including cleft palate,
congenital heart disease, and renal anomalies, were infrequent
or absent in the Ex38/39 KMT2D MVs cohort (Table 2).8
Importantly, the affected individuals in our study did not
display intellectual disability or hypotonia, which are almost
universal features in all patients with KS1. Speech delay noted
in several individuals was attributable to their hearing
impairment. Furthermore, the typical dysmorphic features
of KS1 were not seen in the cohort described here.8 This was
supported by the results of our objective facial analysis studies
(Fig. 2). We found that the DNA methylation pattern of
individuals described here was distinct from what has been
described in KS1. Notably, the DNA methylation studies were
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performed in a small number of individuals and testing in a
larger patient cohort will be required to validate our findings.
Nevertheless, collectively these results strongly suggest that
the restricted spectrum of KMT2D missense variants in exon
38 and 39 identified in this study result in a multiple
malformation disorder that is genetically, phenotypically, and
epigenetically distinct from KS1.
The variants described here are flanked by Val3527 and
Lys3583. However, it remains to be seen if variants outside
this window may also result in the same phenotype.
Furthermore, the phenotype spectrum of individuals
described here is very wide, ranging from early death of three
individuals (from families 3 and 4) to a relatively mild
phenotype (e.g., the affected mother in family 6). This may be
due to allelic heterogeneity or other genetic, epigenetic, or
environmental factors. The identification of larger cohorts of
individuals will be required to resolve these questions.
Some features of the Ex38/39 KMT2D MVs cohort overlap
with those of CHARGE syndrome (OMIM 214800), including
coloboma, choanal atresia, and ear anomalies (Table S5).29
However, none of the affected individuals fulfill the clinical
diagnostic criteria for CHARGE syndrome.29 Molecularly,
KMT2D and CHD7 both interact with members of the WAR
complex30 and clinical overlap between KMT2D variants and
CHARGE syndrome has been previously postulated.28,30 Two
of these previous reports described individuals with clinical
features that match those of the Ex38/39 KMT2D MVs cohort
and that carry KMT2D missense variants, one with p.
Gln3575His and another with p.Leu3564Val, that lie within
the central conserved KMT2D region we describe.28,31 We
propose that these previously published individuals have
neither KS1 nor CHARGE syndrome, and fit better with the
condition that we describe in this study. Other disorders that
phenotypically overlap with the condition described here
include branchiootorenal syndrome (BORS, OMIM 113650),
branchiootic syndrome 2 (OMIM 120502), branchiooculofa-
cial syndrome (OMIM 113620), and Bamforth–Lazarus
syndrome (OMIM 241850) (Table S5).
Athelia or hypoplasia of the nipples is a rare clinical feature
of unknown incidence and was present in more than half the
patients in our report. On the contrary, most individuals with
KS1 tend to develop prominent breasts during infancy and
early childhood. A single case report has described an
association between hypoplastic nipples and CHARGE
syndrome.32 The combination of athelia and choanal atresia
is an even rarer association, previously only described in
carbimazole embryopathy.33 In the absence of an antenatal
history of maternal carbimazole use, this combination of
features would be very suggestive of the condition described
in this paper. Of note, carbimazole is a pro-drug that is
converted to methimazole, which inhibits thyroid peroxidase.
We speculate that the KMT2D variants described here
perhaps directly or indirectly result in dysfunction, down-
regulation, or inhibition of thyroid peroxidase or develop-
mental pathways involving this enzyme. On review of the
literature with a focus on the combination of choanal
atresia and athelia, we identified two previous case reports
describing features very similar to the families described here
including athelia, choanal atresia, failure to thrive,
congenital cardiac disease, and preauricular pits.34,35 Due to
the clinical similarities, we suspect that our report provides a
possible explanation for the etiology of disease in these
historical cases.
In contrast to the observations for individuals with Kabuki-
causing KMT2D missense variants,17 the H3K4 methyltrans-
ferase activities of the variants described here were normal
(Fig. S6). Notably, KMT2D also possesses H3K4 me1 and me2
methyltransferase activity that we have not tested. However,
given the genetic and clinical findings, it appears unlikely that
the phenotype results simply from the loss of H3K4
methyltransferase function. Importantly, the variants identi-
fied in this study are in a highly conserved central region that
contains predicted coiled-coil domains (Fig. 1b) as well as
short polyQ tracts (Fig. S1). The polyQ tracts at the C-
terminus end of the highly conserved central region are likely
to be unstructured and to destabilize coiled-coil formation,
potentially with the formation of intrinsically disordered
regions of secondary protein structure. The results of our CD
experiments (Fig. 3) suggest that the central region of
KMT2D is indeed disordered, which is consistent with the
usual major roles of intrinsically disordered regions in
mediating and modulating protein–protein interactions.4,36
However, pathogenic missense variants in the central region,
as in the Ex38/39 KMT2D MVs cohort, could prevent normal
transitions between disordered and ɑ-helical structure in a
coiled-coil domain, or reduce the levels of intrinsic disorder,
thereby disrupting normal specific protein–protein interac-
tions in the KMT2D chromatin remodeling complex.
In the peripheral blood of affected individuals one of the
most significant hypomethylated DMRs that we observed
encompasses the transcription start site (TSS) region of
HOXA2 (OMIM 604685), variants in which cause autosomal
dominant microtia with or without hearing impairment
(612290) (Fig. S4). HOXA2 is a fundamental transcriptional
factor that regulates EYA1 (linked with BORS) and orches-
trates morphogenesis of the auricle. Notably, ear anomalies
were seen very frequently in the Ex38/39 KMT2D MVs
cohort. We also identified hypermethylation in the gene body
of PAX8 (OMIM 167415), variants in which cause congenital
hypothyroidism due to thyroid dysgenesis or hypoplasia
(OMIM 218700) (Fig. S4). Hypothyroidism was a frequent
feature in the Ex38/39 KMT2D MVs cohort. Furthermore, a
few CpG sites corresponding to genes involved in neural crest
development showed altered DNA methylation pattern. In
particular, we observed hypomethylation in the regions
corresponding to ZIC3 (OMIM 300205), TFAP2E (OMIM
614428), and SOX10 (OMIM 602229) and a hypermethylation
in the region corresponding to ZEB2 (OMIM 605802).
All these regulators influence neural crest migration.37
Although the expression of these genes requires to be tested
in relevant tissue, our results suggest that the variants
described in this study might be deleterious to the normal
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expression or function of key transcription factors that might
impair specific developmental processes.
In summary, we describe a variable disorder caused by
missense variants in parts of exons 38 and 39 of KMT2D that
is clinically, genetically, and epigenetically distinct from KS1.
This condition is characterized by anomalies of the branchial
arch, ears, choanae, lacrimal ducts, nipples, thyroid, growth,
and the immune system. This work provides insights into the
diverse roles of KMT2D in embryonic development and
uncovers the importance of a previously unstudied region of
this critical protein that is likely to be an intrinsically
disordered region that mediates and modulates
protein–protein interactions. Further work will be required
to determine the link between the KMT2D variants described
here and the human and cellular phenotypes observed.
Overall, this work emphasizes the possibility of undiscovered
phenotypes linked with even well-studied genes.38,39
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